Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a hold rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

Several other research firms also recently issued reports on COLL. Piper Sandler dropped their price target on Collegium Pharmaceutical from $43.00 to $28.00 and set a “neutral” rating on the stock in a research note on Friday. Barclays reduced their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, August 19th. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a report on Friday. Zacks Research upgraded Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, October 15th. Finally, Truist Financial began coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $44.88.

Get Our Latest Analysis on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $24.71 on Friday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The stock has a market cap of $804.56 million, a price-to-earnings ratio of 3.39, a PEG ratio of 0.74 and a beta of 0.75. The business has a 50 day simple moving average of $22.98 and a 200 day simple moving average of $32.68. Collegium Pharmaceutical has a 52-week low of $21.43 and a 52-week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.10. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $216.34 million during the quarter, compared to analysts’ expectations of $216.03 million. During the same quarter in the prior year, the company earned $2.25 earnings per share. The business’s quarterly revenue was up 67.4% compared to the same quarter last year. Analysts anticipate that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth about $196,972,000. Jupiter Topco LLC acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $77,743,000. Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $9,882,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $8,506,000.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

See Also